Search Results 2021-2030 of 17047 for monoclonal antibody

1. A Study to Evaluate Interferon-gamma in Antifungal Immunity - Mayo Clinic

   Solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients are at increased risk for invasive fungal infections. Mortality rates ...

2. A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302) - Mayo Clinic

   Subjects with evidence of positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). NOTE: if a subject tests negative for HBsAg ...

3. Study of INCB053914 in Subjects With Advanced Malignancies - Mayo Clinic

   Participation eligibility · < 5 half-lives or 14 days, whichever is longer, for any investigational agent; · < 28 days for any antibodies or biological therapies; ...

4. Clinical Trials - AUTO1 in Relapsed or Refractory B-ALL

   Treatment with any T cell lytic or toxic antibody (e.g., alemtuzumab) within 6 months prior to leukapheresis, or treatment with clofarabine or cladribine within ...

5. Immunostains Laboratory - Division of Anatomic Pathology - Mayo Clinic

   The Immunostains lab performs immunohistochemistry (IHC), in-situ hybridization (ISH) and mass spectrometry-based proteomic (MS) clinical diagnosis tests.

6. Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - Mayo Clinic

   ... antibody or systemic chemotherapy within 4 weeks before first dose of study treatment. * Any complementary medications (eg, herbal supplements or ...

7. A Study to Compare the Effectiveness, Safety and Tolerability of P1101 vs. Anagrelide for Essential Thrombocythemia - Mayo Clinic

   Interferon treatment-naïve, or anti-P1101 binding antibody negative at screening and the washout between last dose of interferon and randomization should ...

8. A Study of Patients Treated for Wiskott-Aldrich Syndrome Since 1990 - Mayo Clinic

   ... antibody response to polysaccharide antigens or low IgM. Longitudinal Analysis (Retrospective and Prospective). For stratum A, participants with WAS who have ...

9. Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab to Treat Richter Transformation - Mayo Clinic

   Hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative, and hepatitis B PCR positive will be excluded; These above patients once ...

10. Science Saturday: Uncovering disparities in local communities - the case of the HPV vaccine - Mayo Clinic News Network

    What can we do about it? Sharing Mayo Clinic: An uncommon antibody, a life restored. Related Articles. Featured News. Harnessing telehealth to enhance patient ...